EUVIMEDOpdag EUVIMED
Klinische StudieOpen access · CC BY-NC-ND 4.0

Magnetic resonance‐guided high‐intensity focused ultrasound ( MR ‐ HIFU ) therapy of uterine fibroids effectively reduces both bleeding and bulk symptoms—A prospective single‐center 12‐month follow‐up study

Saara Otonkoski, Antti Viitala, Gaber Komar, Teija Sainio iD, Anna Yanovskiy, Ina Lehtonen, Roberto Blanco Sequeiros, Antti Perheentupa, Kirsi Joronen

Acta Obstetricia et Gynecologica Scandinavica · 2026-09 · 105 (9) · 1840-1847

DOI: 10.1111/aogs.70268 ↗

At a glance

Klinische Studie in Acta Obstetricia et Gynecologica Scandinavica, published online on 2026-06-15. Written by Saara Otonkoski and 8 co-authors. Institution: Department of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland. Major MEDLINE topics: High-Intensity Focused Ultrasound Ablation, Leiomyoma, Magnetic Resonance Imaging, Interventional, Uterine Hemorrhage. 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Government Research Foundation of Finland.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Uterine fibroids are common benign neoplasms in women. Magnetic resonance‐guided high‐intensity focused ultrasound (MR‐HIFU) is a noninvasive treatment that has been shown to reduce fibroid‐related symptoms and improve quality of life (QoL). In this study, we aimed to clarify symptom reduction in patients with isolated bleeding or bulk symptoms. Material and Methods This prospective study with a 12‐month follow‐up included 163 women with uterine fibroids causing either bleeding or bulk symptoms and deemed suitable for MR‐HIFU treatment. Treatments were carried out using an extracorporeal tabletop MR‐HIFU system (Sonalleve V2, Profound Medical Inc., Mississauga, Canada). The non‐perfused volume ratio (NPV%) was determined after treatment. Symptom severity and QoL were assessed using the Uterine Fibroid Symptom and Quality of Life questionnaire at baseline, 3 months, and 12 months after treatment. The study was registered at ClinicalTrials.gov (NCT02914704).

Results

A total of 122 women with bleeding and 41 women with bulk symptoms were included. The overall mean NPV% for all patients was 62%. The median symptom severity score (SSS) at baseline was 56 (IQR 47–69) and 46 (34–63), at 3 months 28 (16–44) and 19 (6–30), and at 12 months 25 (13–31) and 19 (6–41) for the bleeding and bulk groups, respectively. The reduction of SSS was statistically significant between baseline and 3 months ( p < 0.001) and between baseline and 12 months ( p < 0.001) in both groups. The median of QoL at baseline was 43 (IQR 31–58) and 74 (45–83), at 3 months 70 (53–82) and 89 (74–97), and at 12 months 82 (69–91) and 82 (67–100) for the bleeding and bulk groups, respectively. In the bleeding patients, the increase in QoL was statistically significant between all the time points compared ( p < 0.05). In the bulk group, the increase in QoL was statistically significant from baseline to 3 months ( p < 0.001) and from baseline to 12 months ( p < 0.01).

Conclusions

MR‐HIFU resulted in significant symptom reduction and improved QoL in patients with both bleeding and bulk‐related fibroid symptoms. When successful, MR‐HIFU provides effective and rapid symptom relief for both symptom types.

Subjects

MeSH terms (MEDLINE)

High-Intensity Focused Ultrasound AblationLeiomyomaMagnetic Resonance Imaging, InterventionalUterine HemorrhageUterine NeoplasmsAdultFemaleHumansMiddle AgedFollow-Up StudiesProspective StudiesQuality of LifeTreatment Outcome

Author keywords

MR‐HIFUbleedingbulk symptomsfibroidquality of life

Authors and institutions

  • Department of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland.
  • Faculty of Medicine, University of Turku, Turku, Finland.
  • Department of Radiology, Turku University Hospital, Turku, Finland.
  • Department of Medical Physics, Turku University Hospital, Turku, Finland.

ORCID profiles: Teija Sainio

Funding

  • Government Research Foundation of Finland

Cite

APA

Otonkoski, S., Viitala, A., Komar, G., Sainio, T., Yanovskiy, A., Lehtonen, I., Blanco Sequeiros, R., Perheentupa, A., & Joronen, K. (2026). Magnetic resonance‐guided high‐intensity focused ultrasound ( MR ‐ HIFU ) therapy of uterine fibroids effectively reduces both bleeding and bulk symptoms—A prospective single‐center 12‐month follow‐up study. Acta Obstetricia et Gynecologica Scandinavica, 105(9), 1840-1847. https://doi.org/10.1111/aogs.70268

Vancouver

Otonkoski S, Viitala A, Komar G, Sainio T, Yanovskiy A, Lehtonen I, et al. Magnetic resonance‐guided high‐intensity focused ultrasound ( MR ‐ HIFU ) therapy of uterine fibroids effectively reduces both bleeding and bulk symptoms—A prospective single‐center 12‐month follow‐up study. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(9):1840-1847. doi:10.1111/aogs.70268

BibTeX
@article{Otonkoski2026,
  author = {Otonkoski, Saara and Viitala, Antti and Komar, Gaber and Sainio, Teija and Yanovskiy, Anna and Lehtonen, Ina and Blanco Sequeiros, Roberto and Perheentupa, Antti and Joronen, Kirsi},
  title = {Magnetic resonance‐guided high‐intensity focused ultrasound ( MR ‐ HIFU ) therapy of uterine fibroids effectively reduces both bleeding and bulk symptoms—A prospective single‐center 12‐month follow‐up study},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2026},
  volume = {105},
  number = {9},
  pages = {1840--1847},
  doi = {10.1111/aogs.70268}
}
Start for free →